Concat Lp v. Unilever, Plc

350 F. Supp. 2d 796, 2004 U.S. Dist. LEXIS 27169, 2004 WL 2913636
CourtDistrict Court, N.D. California
DecidedSeptember 7, 2004
DocketC 04-1396 SI
StatusPublished
Cited by78 cases

This text of 350 F. Supp. 2d 796 (Concat Lp v. Unilever, Plc) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Concat Lp v. Unilever, Plc, 350 F. Supp. 2d 796, 2004 U.S. Dist. LEXIS 27169, 2004 WL 2913636 (N.D. Cal. 2004).

Opinion

ORDER GRANTING DEFENDANTS’ MOTION TO STAY PENDING ARBITRATION, DENYING DEFENDANTS’ MOTION TO DISMISS, AND GRANTING PLAINTIFFS’ MOTION TO DISQUALIFY DEFENDANTS’ COUNSEL

ILLSTON, District Judge.

On July 2, 2004, this Court heard argument on the following motions: defendants’ motion to stay this litigation pending arbitration or, in the alternative, to dismiss the complaint on grounds of forum non conveniens, lack of in personam jurisdiction, and/or failure to join indispensable parties; and plaintiffs motion to disqualify defendants’ counsel. Having carefully considered the argument of counsel and the papers submitted, the Court hereby GRANTS defendants’ motion to stay the action pending arbitration; DENIES defendants’ motion in the alternative to dismiss; and GRANTS plaintiffs’ motion to disqualify counsel.

*800 BACKGROUND

The dispute in this case is about intellectual property rights concerning a group of chemical compounds and methods of using those compounds in the formulation of deodorants. The compounds in question are chelators. Chelators have the active property of combining with metal ions to form further compounds, known as chelates. Due to their metal-binding properties, che-lators tend to inhibit chemical reactions. NIH Unified Medical Language System, U.S. National Medical Library, < http://ghr.nlm.nih.gov/ghr/glossary/che-lator > (last visited July 1, 2004).

Plaintiff Concat LP is a California Limited Partnership whose partners are members of the Winchell family. Compl. at ¶ 1; Declaration of Dr. H.S. Winchell, ¶ 2. During most of the period covered by this dispute, the managing partner was Dr. H.S. Winchell. Winchell Decl. at ¶¶ 1-2. The current managing partner is a corporation owned by Dr. • Winchell’s children. Id. at ¶ 2. Concat’s business includes the design and development of chelators and their applications. Compl. at ¶ 16. Between 1981 and 2001, Concat supported all research and development at Israel Resources Corporation, Ltd. (“IRC”), a private company organized under the law of Israel. IRC assigned all intellectual property rights arising from this research to Concat. Compl. at ¶ 3; Winchell Decl. at ¶ 3. In June, 1996, Concat filed an international patent application covering a number of inventions, including methods of using chelators to prevent bacterial and fungal growth on human body surfaces. Compl. at ¶ 18. On September 10, 2001, Concat assigned all of its then current intellectual property rights to Chelator, LLC, a Delaware limited liability company with its principal place of business in Concord, California. In return, Concat received all Chelator stock issued at that time. Id. at ¶¶ 2, 4. IRC then sold all of its assets, including intellectual property rights, to Complexx R & D services, a private company organized in Israel and wholly ’ owned by Chelator. Id. at ¶ 5.

Defendants Conopeo, Unilever UK and Unilever U.S. are subsidiaries of Unilever PLC, and Unilever N.V., which are organized under the laws of the U.K. and the Netherlands, respectively, but which operate as a single company and have a single board of directors. Compl. at ¶¶ 7-12. Unilever is .a major international producer of consumer goods, including toiletries. Id. In August, 1996, Dr. Winchell of Con-cat and the then president of IRC, Dr. Haim Zaklad, contacted Unilever regarding a possible joint development of Con-cat’s compounds for use in deodorants. Compl. at ¶ 19. On December 12, 1996, a Letter of Understanding was executed between IRC and Unilever U.K. Central Resources Ltd., acting on behalf of its Unilever Research Port Sunlight Laboratory (“Port Sunlight”), located in Wirral, U.K. Id.; Decl. of Paul W. Vapnek in Supp. of Pis.’ Mot. to Stay or Dismiss, Ex. 5. The 1996 Letter of Understanding was followed by a “Secrecy Agreement,” executed in June, 1997, between IRC and the Unilever Research and Engineering Environmental Safety Laboratory (“ESL”), later renamed the Unilever Research SEAC Toxicology Unit (“SEAC”), located in Bedford, U.K. Compl. at ¶ 22; Decl. of Jason Lief in Supp. of Defs.’ Mot. to Stay or Dismiss, Ex. B. The scope of the 1997 Secrecy Agreement, which includes an arbitration clause, is a matter in dispute. See Lief Decl., Ex. B at ¶ 5. Pursuant to the 1996 Letter of Understanding, IRC provided Unilever with samples of two compounds for evaluation, the more important of which was designated 3MP/IRC011 (“3MP”) or Deofix. Compl. at ¶¶ 19-20. Testing and evaluation of the 3MP compound continued for the next several *801 years, during which period the parties conducted extensive discussions and exchanged scientific data. Id. at ¶¶ 21-44. Beginning in May, 1998, Drs. Winchell and Zaklad met and corresponded regularly with Drs. Michael Lowry and Stephen Ma-kin of the Port Sunlight Deodorant Research Group. Compl. at ¶¶ 24-44. On February 1, 1999, the IRC and Port Sunlight entered a further “Confidentiality Agreement.” Id. at ¶ 28; Vapnek Decl. in Supp. of Pis.’ Mot. to Stay or Dismiss, Ex. 11.

Beginning in January, 2001, Unilever filed a series of U.S. patent applications under the titles: “Deodorant Products,” “Anti-Microbial Compositions,” and “AntiMicrobial Antiperspirant Products,” all naming Dr. Makin as an inventor. Compl. at ¶¶ 47-52. The “Deodorant Products” application issued in January, 2003, as U.S. Patent Number 6,503,490 B2 (“the ’490 patent”). Id. at ¶ 47. In April, 2002, Unilever announced a “breakthrough” deodorant technology employing a chemical that inhibits the growth of bacteria by binding the nutrient iron in sweat. Id. at ¶ 45. In September, 2002, Drs. Makin and Lowry presented a scientific conference paper entitled “Iron Sequestration on Skin: A New Route to Improved Deodorancy.” Id. at ¶ 46. Plaintiffs allege that these patent applications and publications are based on data that Unilever obtained from IRS/Con-cat. Id. at ¶¶ 47-50. Plaintiffs further allege that Unilever has marketed deodorants containing plaintiffs’ intellectual property. Id. at ¶ 54; Winchell Decl. at ¶ 17.

On June 4, 2003, Chelator was awarded U.S. Patent No. 6, 583, 182 B1 (“the ’181 patent”), which claims the use of chelating agents to inhibit bacterial and fungal growth. Winchell Decl. at ¶ 16. The inventors of the ’181 patent include Drs. Winchell and Zaklad. Id.

In late June, 2003, Dr. Winchell and his wife approached W. Scott Thomas, Esq. of the Personal Law Practice Group of the San Francisco office of Morgan, Lewis & Bockius LLP (“Morgan, Lewis”) for assistance with planning his estate. Winchell Decl. at ¶ 4; Decl. of W. Scott Thomas in Supp. of Defs.’ Opp’n to Pis.’ Mot. to Disqualify at ¶ 2. Morgan, Lewis are counsel to Unilever in this dispute. It is undisputed that the Winchells provided Thomas with a list of their and their children’s business interests, including their partnership interests in Concat, and Concat’s interests in Chelator. Winchell Decl. at ¶ 5; Thomas Decl. at ¶¶ 2-3. Thomas used this information to run a conflict of interest search in Morgan, Lewis’s client database.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
350 F. Supp. 2d 796, 2004 U.S. Dist. LEXIS 27169, 2004 WL 2913636, Counsel Stack Legal Research, https://law.counselstack.com/opinion/concat-lp-v-unilever-plc-cand-2004.